Due to an author miscommunication, the statement published in the above article βThe authors have declared they have no competing interests.β is incorrect. DM Black has received honoraria from Merck and Nycomed, and research support from Novartis. He has also acted as a consultant for Roche. CJ Rosen declared he has no competing interests.
Additional information
The online version of the original article can be found at 10.1038/ncprheum0530
Rights and permissions
About this article
Cite this article
Black, D., Rosen, C. Erratum: Is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis?. Nat Rev Rheumatol 3, 420 (2007). https://doi.org/10.1038/ncprheum0563
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0563
